Events & Trainings

Current meetings, workshops, education

Academic Events

As a specialist scientific organisation, we hold many challenging events every year.

In a two-year cycle, the AGAH holds an acclaimed scientific congress in Germany, where relevant topics that interest our members are discussed – alternating with a scientific event with one of our partner organisations, AHPPI in UK, Bapu in Belgium or Association Française de Pharmacologie Translationelle (AFPT) -Le Club Phase I in France.

In addition, scientific workshops are held on special topics and there is a yearly national discussion round together with the BfArM, where mostly safety-relevant matters in early-phase clinical studies are discussed. The programme is rounded off with training courses, entitled Introductory or Applied Workshops for young scientists and a training programme specifically for study nurses.

  • DETAILS

    AGAH Mebinar | Rare Diseases

    Digital Event  |  Nov 19 - Nov 19, 2025  |  17:30 – 19:00

    - Innovative Approaches to Clinical Trials in Rare Diseases

  • DETAILS

    AGAH Workshop | AI in Clinical Pharmacology

    nH collection Köln Mediapark  |  Nov 21 - Nov 21, 2025  |  09:00 – 17:00

    - Enhancing Drug Therapy and Study Conduct

  • DETAILS

    AGAH Mebinar | Patient Engagement in Early Phase Trials

    Digital Event  |  Jan 14 - Jan 14, 2026  |  17:30 – 19:00

    - Einbindung von Patientinnen und Patienten in die Planung von Entwicklungskonzepten sowie in konkrete Aspekte klinischer Prüfungen

  • DETAILS

    AGAH Workshop | Physiology-Based Pharmacokinetic (PBPK) model application

    Haus am Dom - Katholische Akademie Rabanus Maurus  |  Feb 24 - Feb 24, 2026  |  13:00 – 17:30

    in Model-Informed Drug Development (MIDD) -As part of the AGAH Conference. Can also be booked individually.-

  • DETAILS

    11th German Pharm-Tox Summit

    Partner-Event  |  Heinrich Heine University Düsseldorf  |  Mar 17 - Mar 20, 2026

    92. Jahrestagung der Deutschen Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie (DGPT)

  • DETAILS

    28th Pharmacokinetics/Pharmacodynamics (PK/PD) Expert Meeting

    Leonardo Weimar  |  Apr 23 - Apr 25, 2026

    This meeting will take place at Hotel Leonardo Weimar under the auspices of AGAH (Arbeitsgemeinschaft für Angewandte Humanpharmakologie e. V.) and starts with a joint Dinner on 23 April 2026. The scientific programme begins on Friday morning, 24 April 2026 and ends on Saturday, 25 April 2026 at lunchtime.

  • DETAILS

    AGAH Workshop Toxic Truths and Dosing Dilemmas:

    SocraTec R&D Oberursel  |  May 7 - May 8, 2026  |  13:00 – 13:00

    Navigating Early CNS Drug Development

  • DETAILS

    Introductory Course in Exploratory Medicines Development – Part I online (6 half-days)

    Digital Event  |  Oct 22 - Nov 6, 2026

    This course addresses postgraduates in life sciences interested in early clinical development of medicinal products. Two training parts of several days provide a concise overview on Human Pharmacology / Translational Medicine spanning from non-clinical pharmacology and toxicology over first-in-man studies to proof-of-concept clinical trials.

  • DETAILS

    Introductory Course in Exploratory Medicines Development – Part II face2face

     |  Nov 24 - Nov 27, 2026

    This course addresses postgraduates in life sciences interested in early clinical development of medicinal products. Two training parts of several days provide a concise overview on Human Pharmacology / Translational Medicine spanning from non-clinical pharmacology and toxicology over first-in-man studies to proof-of-concept clinical trials.

AGAH e.V.
AGAH Mebinar | Rare Diseases

- Innovative Approaches to Clinical Trials in Rare Diseases

Nov 19 - Nov 19, 2025  |  17:30 – 19:00
Program Information

Rare diseases present significant challenges for physicians, researchers, and the pharmaceutical industry. Small patient populations, heterogeneous clinical presentations, diagnostic challenges due to technical limitations, and limited data sources complicate both clinical care and drug development. Yet, innovative methodologies and operational strategies—together with advanced data analyses—offer opportunities to bridge these gaps and accelerate the development of targeted therapies for patients living with rare diseases.

We are pleased to invite you to this enlightening mebinar featuring:

•    Dr Maria Burian (iGenePharma) – how the integration of real-world evidence and modelling and simulation at iGenePharma can help overcome methodological barriers in the design
•    of clinical trials in rare diseases.
•    Dr Christoph Coch (Debra Research) – providing insights into the potential role of non-profit patient organisations in advancing clinical research for rare diseases, using DEBRA Research and the rare genetic skin disease Epidermolysis Bullosa as an example.
•    Kathrin Dieter (Rheacell) – sharing real-world insights from RHEACELL on navigating operational challenges from early to late-stage pivotal clinical trials in the rare genetic skin disease Epidermolysis Bullosa. 

Objective
This mebinar aims to provide participants with an overview of innovative methodological and operational approaches to enhance the efficiency and success of clinical trials in rare diseases.

Registration Information

AGAH Member - 0 EUR
Guest - 40 EUR

Registration welcome until 17 November 2025 (= dispatch of dial-in details)

AGAH Workshop | AI in Clinical Pharmacology

- Enhancing Drug Therapy and Study Conduct

Nov 21 - Nov 21, 2025  |  09:00 – 17:00
Programme

By the end of this workshop, participants will:

✅ Understand the fundamentals of AI in clinical pharmacology

✅ Explore AI applications in drug discovery, dosing, and adverse event prediction

✅ Gain hands-on experience with AI tools and case studies

✅ Discuss ethical and regulatory considerations

Workshop Requirements

✅ Basic knowledge of pharmacology
✅ Laptop/tablet for hands-on exercises
✅ Pre-reading materials (AI in healthcare basics)

Detailed programme PDF:

Registration Information

Registration welcome until 7 November 2025

Event Location
nH collection Köln Mediapark
Im Mediapark 8b,
50670 Köln
AGAH Mebinar | Patient Engagement in Early Phase Trials

- Einbindung von Patientinnen und Patienten in die Planung von Entwicklungskonzepten sowie in konkrete Aspekte klinischer Prüfungen

Jan 14 - Jan 14, 2026  |  17:30 – 19:00
Program Information

Die Einbindung von Patientinnen und Patienten in die Planung von Entwicklungskonzepten sowie in konkrete Aspekte klinischer Prüfungen der Phasen II bis IV – bis hin zur patientengerechten Kommunikation von Studienergebnissen – ist mittlerweile auf europäischer und globaler Ebene zumindest theoretisch etablierter Standard.

In der Praxis bestehen jedoch noch erhebliche Lücken und Wissensdefizite hinsichtlich geeigneter Vorgehensweisen.
Über die Vorteile, die Notwendigkeit und die möglichen Hürden einer Einbindung gesunder Probandinnen und Probanden in die Konzeption und Planung von Phase-I-Studien wurde bisher kaum nachgedacht.

Eine große europäische Umfrage der EUFEMED zu diesem Thema hat interessante und teilweise unerwartete Ergebnisse hervorgebracht. Es erscheint daher lohnend, diese Option konkret zu diskutieren – nicht nur aus ethischen, sondern auch aus praktischen Gründen.

In diesem Mebinar wollen wir gemeinsam erörtern, ob und wie die Einbindung von Probandinnen und Probanden zu einem Standortvorteil für die Humanpharmakologie in Deutschland werden könnte.

Referentin:    Dr. Ingrid Klingmann, Pharmaplex bv, Wezembeek-Oppem


Bitte reichen Sie gern vorab Fragen, bis 09.01.2026, über die Anmeldemaske ein!

Registration Information

AGAH Member - 0 EUR
Guest - 40 EUR

Anmeldung willkommen bis 12.01.2026 (= Versand der Einwahldaten)

AGAH Conference 2026

"Optimism, Courage, and Pragmatism – Human Pharmacology 2030"

Feb 24 - Feb 26, 2026
Become a Sponsor and/or Exhibitor

We kindly invite you to support us as an exhibitor and/or sponsor to help making this significant event a success and enhance the experience for all participants. We offer a range of sponsorship and exhibition options, each accompanied by promotional benefits for your company. Please refer to the brochure for more details. Please request these from our Conferenc office: agah-meetings@csihamburg.de

By sponsoring this event, your Company will expand visibility among key opinion leaders in early-phase development, regulatory authorities, ethics committees, and industry professionals. This is an excellent opportunity to showcase your commitment to advancing innovative medicines and supporting state-of-the-art clinical research.

PROGRAMME SCHEDULE AT A GLANCE


Thuesday, 24th February 2026
Pre-Meeting Workshop | 13:00–17:30
"Physiology-Based Pharmacokinetic (PBPK) model application in Model-Informed Drug Development (MIDD)"

AGAH Mitgliederversammlung/General Assembly | 19:00

Wednesday, 25th February 2026 | 09:00–18:00
Session 1 | Session 2 | Session 3
Conference Get-Together | 18:00–20:30

Thursday, 26th February 2026 | 07:30–14:00
AGAH Breakfast Session – Meet the Expert
Session 4 | Session 5 | Session 5
Concluding, Recap and Farewell

Download conference fees and programme PDF:

Registration Information

Early registration fees: until 31th October 2025


Registration Link:

CALL FOR ABSTRATCS – Deadline Extension until 17 November 2025

The Organizing Team of the AGAH Conference 2026 invites abstracts for poster presentation at the conference dealing with any of the following aspects of medicines development in humans.
• Model-Informed Drug Development – Progress and Outlook
• Dose Selection for Phase 2 and Phase 3 – Optimal and Optimus
• Overly Complex Early Phase Trials – Disruptive Proposals for Improvement
• Artificial Intelligence Impacting Clinical Pharmacology – A Dynamic Field of   Opportunities
• Regulatory Enablers of Innovative Early Medicines Development

The early registration fee will be reduced by 100 € if you present a poster at the Annual Conference. Please submit your abstract as a pdf using this template:

Event Location
Haus am Dom - Katholische Akademie Rabanus Maurus
Domplatz 3
AGAH Workshop | Physiology-Based Pharmacokinetic (PBPK) model application

in Model-Informed Drug Development (MIDD) -As part of the AGAH Conference. Can also be booked individually.-

Feb 24 - Feb 24, 2026  |  13:00 – 17:30
Program Information

Programme Draft by:

AGAH Conference

Registration Information

Early registration fees: until 31th October 2025

-As part of the AGAH Conference. Can also be booked individually.-

Event Location
Haus am Dom - Katholische Akademie Rabanus Maurus
Domplatz 3
11th German Pharm-Tox Summit

92. Jahrestagung der Deutschen Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie (DGPT)

Mar 17 - Mar 20, 2026
Place your research on the stage

Welcome to the 11th German Pharm-Tox Summit 2026
in cooperation with
the Association for Applied Human Pharmacology (AGAH),
and the Dutch Society of Toxicology (NVT)

Join us in shaping the future of pharmacology and toxicology. Submit an abstract and take the opportunity to present your findings to the plenum. By submitting your abstract you become part of the scientific program and get the chance to share your scientific expertise with your colleagues!
All abstracts will be published as a supplement of "Naunyn-Schmiedeberg's Archives of Pharmacology" (Springer Verlag). 
Your contribution may be selected for a poster prize or a young investigator award.

Take your chance – Submit your abstracts by 1 October 2025!

https://gpts-kongress.de/program-abstracts/abstract-submission

Registration Information

Veranstalter

 •    German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT)
•    German Society for Pharmacology (DGP)
•    German Society for Toxicology (GT)
•    German Society for Clinical Pharmacology and Therapy (DGKliPha)


Tagungsleitung

Univ.-Prof. Dr. med. Maria Grandoch, M.Sc.
Prof. Dr. Jens W. Fischer
Prof. Dr. rer. nat. Gerhard Fritz

Fachgebiete

Pharmacology, clinical pharmacology and toxicology General Medical Research Food & Product Safety Pharmacy, Pharmaceutical/Bio/Medical Chemistry Biotechnology Environmental Medicine

Kongresssprache

Englisch

Additional Information
Event Location
Heinrich Heine University Düsseldorf
Building: 22.01,
Roy Lichtenstein,
40225 Düsseldorf
Event Manager
Conventus Congressmanagement & Marketing GmbH
28th Pharmacokinetics/Pharmacodynamics (PK/PD) Expert Meeting

This meeting will take place at Hotel Leonardo Weimar under the auspices of AGAH (Arbeitsgemeinschaft für Angewandte Humanpharmakologie e. V.) and starts with a joint Dinner on 23 April 2026. The scientific programme begins on Friday morning, 24 April 2026 and ends on Saturday, 25 April 2026 at lunchtime.

Apr 23 - Apr 25, 2026
Program Information

Programme to follow


Registration Information

Start you registration from 15 November 2025 - Book your seat in time - number of participants is limited.

The conference fee includes also the accommodation costs, further information is available within the registration.


PLEASE START YOUR

Awards

Young scientists: Hans Günter Schäfer Award
Generous donations have enabled the Organizing Committee of the PK/PD Expert Meeting to reward outstanding contributions to the PK/PD field by young scientists with the Hans Günter Schäfer Award (cash amount of 1.000 EUR plus free meeting participation incl. travel expenses) issued in memory of the original initiator of the PK/PD Expert Meeting. The award is kindly sponsored by the Frankfurt Foundation Quality of Medicines.
If you are a Doctorate student or young scientist (<2 years after PhD degree) and want to apply for this award, send your peer-reviewed, published manuscript as a pdf file to Joachim Höchel - joachim.hoechel[@]bayer.com. Manuscript submissions must be accompanied by a brief description (500 words maximum) of how your manuscript fits into the overall scientific context of the respective research area, with a specific focus on its innovation, methodology and clinical or in vivo relevance. Submission deadline: 28 January 2026; applicant notification by 14 March 2026. The winner will be announced on the website of the PK/PD Expert Meeting and will present their work as part of the main conference.

Master / Doctorate students: Best presentation award
Three young PK/PD scientists will be given the opportunity to give an oral presentation of their work (5 min) as part of the main conference. All invited presenters will participate free of charge (incl. accommodation). The best presenter will be honored and will receive the “Young Scientist Best Presentation Award” plus reimbursement of travel expenses.
If you are a Master thesis or Doctorate student and want to apply for this award, send an abstract (500 words maximum) to Joachim Höchel - joachim.hoechel[@]bayer.com.
Submission deadline: 28 January 2026; applicant notification by 14 March 2026.
Three applicants will be selected and invited for presentation.

Application to both awards is possible. However, expectation is that a dedicated abstract is written for the ‘Best presentation award’, submission of one complete manuscript for both categories will not be accepted.


General Terms of Registration

Event Location
Leonardo Weimar
Belvederer Allee 25,
99425 Weimar
AGAH Workshop Toxic Truths and Dosing Dilemmas:

Navigating Early CNS Drug Development

May 7 - May 8, 2026  |  13:00 – 13:00
Program Information

AGAH Workshop on the Early Safety Assessment of CNS-Active Drugs – 
Concepts, Strategies, and Potential Pitfalls


The development of CNS-active drugs presents unique challenges in safety assessment, requiring robust strategies to identify and mitigate risks early in clinical development. This AGAH workshop will provide an in-depth exploration of translational considerations, risk management strategies, and lessons learned - including those that shaped the 2018 revision of the EMA guideline - designed to critically evaluate and refine decision-making in early-phase trials.

Key questions to be discussed include:
1.    Which results from early safety assessments are most robust from a translational perspective?
2.    What strategies best support human risk/benefit assessment in CNS drug development?
3.    How have regulatory guidelines evolved to improve risk mitigation in first-in-human studies?

Preliminary schedule

Thursday
1:00 - 6:00 pm
Friday
8:30 - 1:00 pm

Real-world examples, both discontinued (such as BIA 10-2474) and marketed drugs, will illustrate these key questions. While focusing on CNS-active drugs, the principles and strategies explored in this workshop offer valuable insights applicable across all therapeutic areas. 


-Detailed programme to follow-


Registration Information

Participation fee

750 € Regular
500 € Member* 
500 € Junior Scientist up to the age of 30
250 € Member of Regulatory Agencies or ethics committees

*of the following EUFEMED society: AGAH, AHPPI, AFPT - Le Club Phase 1, HEALIXIA, POLFEMED

START YOUR:

Event Location
SocraTec R&D Oberursel
Im Setzling 35,
61440 Oberursel
Introductory Course in Exploratory Medicines Development – Part I online (6 half-days)

This course addresses postgraduates in life sciences interested in early clinical development of medicinal products. Two training parts of several days provide a concise overview on Human Pharmacology / Translational Medicine spanning from non-clinical pharmacology and toxicology over first-in-man studies to proof-of-concept clinical trials.

Oct 22 - Nov 6, 2026
Program Information

Learning Outcomes

On successful completion of Part 1, students should be able to demonstrate an understanding / knowledge of the following:

  • principal steps in drug development - from compound selection to marketing application and beyond
  • pertinent issues involved in the undertaking of early clinical research
  •  specific aspects of how to set-up and conduct early phase clinical trials
  •  regulation of medicines in Europe
  • development and review of compound-specific information to ensure adherence to scientific, medical, ethical, and legal provisions
  • integration of pertinent available scientific information into an IB and a clinical trial protocol
  • principles of trial design, protocol submission and clinical conduct
  • selection of appropriate trial population
  • most common early phase clinical trials and their specific requirements
  • assessment and evaluation of safety data from clinical trials
  • relevance of formulation properties and in vitro characteristics of the trial medication for design and planning of an early phase clinical trial
  • basics of pharmacokinetics
  • defining pharmacokinetic (PK) endpoints for early phase clinical trials
  • method validation according to good clinical (GCP) and good laboratory (GLP) practise practical aspects of bioequivalence trials
Registration Information

to follow

Part I - Online

Day 1    22 October 2026 13:00–18:00

Day 2    23 October 2026 13:00–17:00

Day 3    29 October 2026 13:00–18:00

Day 4    30 October 2026 13:00–17:00

Day 5     5 November 2026 13:00–18:00

Day 6     6 November 2026 13:00–17:00

Introductory Course in Exploratory Medicines Development – Part II face2face

This course addresses postgraduates in life sciences interested in early clinical development of medicinal products. Two training parts of several days provide a concise overview on Human Pharmacology / Translational Medicine spanning from non-clinical pharmacology and toxicology over first-in-man studies to proof-of-concept clinical trials.

Nov 24 - Nov 27, 2026
Program Information

Learning Outcomes

On successful completion of Part 2, students should be able to demonstrate an understanding / knowledge of the following:

  • nonclinical pharmacology and toxicology
  • molecular basis of drug actions
  • allometric scaling and dose proportionality assessments based on characteristic PK data
  • defining pharmacodynamic (PD) endpoints and biomarkers
  • differentiating between primary and secondary PK and PD endpoints
  • How to design an early clinical pharmacology developmant plan
  • planning and management of a first-in-man trial
  • principles of data management and information flow
  • principles of reporting and publication
  • principles of medical statistics
  • characteristic issues involved in the development of biologicals and biosimilars

This AGAH course meets the standards for high-quality postgraduate education and training in Medicines Development established by PharmaTrain and has been awarded a PharmaTrain Recognition. The previous courses  were accredited 3 ECTS (Parts I plus II)

Registration Information

to follow

Additional Information

Day 1     24 November 2026, 09:00–18:30

Day 2     25 November 2026, 09:00–18:00

Day 3     26 November 2026, 09:00–17:45

Day 4     27 November 2026, 09:00–15:00

Mandatory Test (conducted online)

                  1 December 2026, 17:00–19:00

Event Location
Oberursel (Germany)

Full commitment for our members

Our office is committed to working for our tasks and our members. You can reach us during normal office hours by phone or, of course, at any time by e-mail.

We will be happy to answer any questions you may have.

The Association for Applied Human Pharmacology (AGAH e.V.)

Association for Applied Human Pharmacology (AGAH)
Arbeitsgemeinschaft für Angewandte Humanpharmakologie e.V.

Sekretariat/Mitgliederverwaltung

Adress: Goernestraße 30
20249 Hamburg

Einstellungen zur Barrierefreiheit

Weitere Informationen zu unseren Maßnahmen zur Verbesserung der Barrierefreiheit finden Sie in der Erklärung zur Barrierefreiheit .